Hosted on MSN5mon
Smaller vial size for Alzheimer's drug could save Medicare hundreds of millions per year
Assuming conservative lecanemab uptake rates of 1.1–2.9% for an estimated 82,000 to 208,000 of eligible people, current vial sizes would lead to an estimated $133 million to $336 million worth ...
Graft Versus Host Disease Market is Projected for Substantial Expansion from USD 1.3 Billion in 2023| DelveInsight
DelveInsight estimates approximately 52K cases of Graft Versus Host Disease in the 7MM. In 2023, the EU4 and the UK recorded ...
Monthly Prescribing Reference1mon
FDA Approves New Vial Sizes for GVHD Treatment Niktimvo
The treatment was approved in 2024 for chronic graft-vs-host disease after failure of at least 2 prior lines of systemic therapy in patients weighing at least 40kg. The Food and Drug ...
Medpage Today on MSN5mon
Alzheimer's Drug in Smaller Vial Sizes Could Save Medicare Hundreds of Millions
Current vial sizes may result in 5.8% of the Alzheimer's disease drug being thrown away, representing $1,619 in wasted ...